Long Beach, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that two posters related to its glaucoma therapeutic candidate, NB1111, will be presented at the 29th Annual Symposium of the International Cannabinoid Research Society. The symposium will be held June 29 - July 4, 2019 at the Marriott North in Bethesda, Maryland. Details of the posters are as follows:
Abstract #87
Development of an Intraocular Pressure Lowering Ophthalmic Formulation Containing the Δ9-Tetrahydrocannabinol (Δ9-THC) Prodrug, Δ9-THC-Val-HS (NB1111)
Abstract #243
Intraocular pressure lowering efficacy of Δ9 – Tetrahydrocannabinol Valine Hemisuccinate loaded nanoemulsion in a normotensive rabbit model
“Emerald Bioscience continues to focus on meeting milestones in the development of cannabinoids to treat diseases of the eye. We are advancing preparations to enter the clinic to conduct a first-in-human study of the prodrug of THC, NB1111, in patients with mild to moderate glaucoma. Additionally, we are exploring additional ocular indications for the cannabinoid derivatives licensed from the University of Mississippi, including the analog of CBD.”
For more information about this conference, please visit: http://www.icrs2019.org/.
About Emerald Bioscience, Inc.
Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.
Emerald Bioscience is part of the Emerald Group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.
For more information, visit www.emeraldbio.life
CONTACT
Emerald Bioscience Investor Relations
Emerald Health Sciences
Karam Takhar
Email: ir@emeraldbio.life
Phone: 949-336-3437
Douglas Cesario
Chief Financial Officer
Email: doug@emeraldbio.life
Phone: 949-336-3437
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.